NDA 021164 · Fabre Kramer
Exxua
Gepirone Hydrochloride · Oral
NovelCDER novel approval, Sep 22, 2023: To treat major depressive disorder
Last checked: Nov 20, 2026Latest source record: Jun 7, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Sep 22, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 0 recruiting
FAERS reports
4
1 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
BOXED WARNING WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1 ) ] . EXXUA is not approved for use in pediatric patients [see Use in Specific Populations (8.4) ] WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thinking and behavior in pediatric and young adult patients taking antidepressants. Closely monitor for worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). EXXUA is not approved for use in pediatric patients ( 8.4 ).
What it is approved for
From the label in effect Jul 14, 2026.
EXXUA is indicated for the treatment of major depressive disorder (MDD) in adults. EXXUA is indicated for the treatment of major depressive disorder (MDD) in adults ( 1 ).
Mechanism: The mechanism of the antidepressant effect of EXXUA is not fully understood but is thought to be related to its modulation of serotonergic activity in the CNS through selective agonist activity at 5HT1A receptors.
Therapeutic areas: Psychiatry
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
4 products under this application
- EXXUA · GEPIRONE HYDROCHLORIDE EQ 54.5MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
- EXXUA · GEPIRONE HYDROCHLORIDE EQ 18.2MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
- EXXUA · GEPIRONE HYDROCHLORIDE EQ 72.6MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
- EXXUA · GEPIRONE HYDROCHLORIDE EQ 36.3MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Gepirone" as an intervention, any sponsor and status, largest first.
University of PennsylvaniaAcademic, hospital or other
NCT00000189 · 41 participants · Start Jan 1990 · Primary completion Feb 1991
Drug: Gepirone · For: Cocaine-Related Disorders
Sites: Philadelphia, Pennsylvania
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- panic attack2
- anger1
- anxiety1
- blood pressure increased1
- drug ineffective1
- headache1
- illness1
- insomnia1
- migraine1
- muscle twitching1
- nervousness1
- overdose1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 4 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effects of Gepirone-ER on Sexual Function in Patients With Major Depressive Disorder.
Lorenz TK, Johnson MF, Clayton AH · J Clin Psychiatry 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Gepirone in the treatment of major depression.
Jenkins SW, Robinson DS, Fabre LF, et al. · J Clin Psychopharmacol 1990 · Clinical Trial, Randomized Controlled Trial
- Ketoconazole Inhibition of Gepirone Biotransformation and Clearance: In Vitro and Clinical Studies.
Yang Z, Hossain MA, Zhang Q, et al. · J Clin Pharmacol 2025 · Clinical Trial, Phase I, Randomized Controlled Trial
- Buspirone and related compounds as alternative anxiolytics.
Taylor DP, Moon SL · Neuropeptides 1991 · Clinical Trial, Review
- Serotonin-1A anxiolytics: an overview.
Feighner JP, Boyer WF · Psychopathology 1989 · Clinical Trial, Review
- Serotonergic anxiolytics and treatment of depression.
Robinson DS, Alms DR, Shrotriya RC, et al. · Psychopathology 1989 · Clinical Trial, Randomized Controlled Trial
Sponsor: Fabre Kramer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.